CVS takes a swing at Bristol Myers and Pfizer, excluding coverage of their megablockbuster Eliquis in 2022
Bristol Myers Squibb brought in more than $9 billion in sales from its anticoagulant Eliquis in 2020, and it continues to see growth with more than $8 billion in sales in the first nine months of 2021 (nearly $4.5 billion of which went to Pfizer in 2021 as part of their partnership).
But in 2022, one of the largest PBMs in the US, CVS Caremark, has recently decided to no longer cover the megablockbuster, and instead will only offer coverage for warfarin and Janssen’s Xarelto.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
